Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (November 2020)

54 slides from Zynerba Pharmaceuticals's investor presentation, Nov 9, 2020

  1. Slide 1: Corporate Overview November 2020

    Corporate Overview November 2020

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S

  3. Slide 3: A Rare/Near-Rare Neuropsychiatric Company

    Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline focused on high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel ™ (Cannabidiol Gel) • Currently pursuing four neuropsychiatric indications: • Fragile X synd

  4. Slide 4: Deep Clinical Pipeline

    Deep Clinical Pipeline 4 Zygel Cannabidiol Gel Expected Milestones Meet with FDA to discuss pivotal results in patients with a fully methylated FMR1 gene in 4Q2020; outcome also expected in 4Q2020 Discuss Phase 2 results and clinical path forward with FDA in 1H2021 Completion of enrollment once COVI

  5. Slide 5: Zygel (ZYN002) Cannabidiol Gel

    Neuropsych Indications Differentiated Formulation delivers Cannabidiol through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol Gel 5 Unique Mechanism of Action First & only patent - protected (2038), permeation - enhanced, pharmaceutically - produced Cannabidiol gel Transder

  6. Slide 6: Fragile X Syndrome (FXS)

    Fragile X Syndrome (FXS) 6

  7. Slide 7: Fragile X Syndrome (FXS) Overview

    Fragile X Syndrome (FXS) Overview 7 • Rare genetic developmental disability • Leading known cause of both inherited intellectual disability and autism spectrum disorder • Symptoms linked to deficiencies in the endocannabinoid system (ECS) • System of neurotransmitters regulates emotional responses,

  8. Slide 8: FMR1 gene and methylation in FXS

    8 • FMR1 gene codes for production of FMRP* which is vital to synapse development • Mutation manifests as multiple repeats of a DNA segment (CGG) in FMR1 • No Fragile X: Segment repeats 5 to 40 times; normal production of FMRP • Premutation Fragile X: Segment repeats 50 to 200 times; reduced FMRP pr

  9. Slide 9: Proposed MOA of Cannabidiol in patients with FXS and fully methylated FMR1 gene

    Proposed MOA of Cannabidiol in patients with FXS and fully methylated FMR1 gene 9 • FMRP affects multiple intracellular processes • Endocannabinoid system • Glutamate and GABA feedback loops • FMet patients • Males produce no FMRP • Females have significant reduction in FMRP • Absence or loss of FMR

  10. Slide 10: CONNECT-FX: A Pivotal Trial In FXS

    CONNECT - FX: A Pivotal Trial In FXS 10 C linical study O f Ca NN abidiol in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel (n=110) 250 mg daily 500 mg daily (weight - based dose) Placebo (n=102) Mirrors Zygel administration Treatment 212 patients randomized Three through 17 yea

  11. Slide 11: CONNECT-FX Baseline Characteristics

    11 CONNECT - FX Baseline Characteristics Placebo Zygel Total n 102 110 212 Age (years) 9.8 9.6 9.7 Sex – Males , n (%) 78 (76%) 81 (74%) 159 (75%) Weight (kg) Median 34.3 36.8 35.7 Range (Min, Max) 15.6, 104.7 14.6, 87.0 14.6, 104.7 >35kg, % 48% 56% 52% Baseline psychoactive medications, % 66% 57% 6

  12. Slide 12: CONNECT-FX: Qualitative Caregiver Reported Behavioral Survey

    12 CONNECT - FX: Qualitative Caregiver Reported Behavioral Survey Top 10 Classifications of Behavioral Challenges Utilizing the Qualitative Caregiver Reported Behavioral Survey, caregivers were asked to describe their most important behavioral challenges at baseline 66% 42% 33% 30% 29% 28% 26% 23% 2

  13. Slide 13: CONNECT-FX: A Pivotal Trial In FXS

    CONNECT - FX: A Pivotal Trial In FXS 13 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/L

  14. Slide 14: CONNECT-FX: Rationale for Pre-Planned Ad Hoc Analysis

    14 • Methylation of genes is considered to be important in numerous pathological disorders including FXS • Methylation has been associated with the mechanism of mGluR5 in FXS • Currently, treatment options are limited for many of these disorders • The degree of methylation can influence the severity

  15. Slide 15: CONNECT-FX Patients: Full Data Set, FMet and Non-FMet Groups

    CONNECT - FX 15 Patients Full Data Set FMet Group Non - FMet Group Randomization (ITT) 212 169 42 Full Analysis set 210 167 42 • One patient did not receive study medication after randomization and one patient did not have post - baseline efficacy assessments resulting in 210 patients in Full Analys

  16. Slide 16: CONNECT-FX: Demographics and Baseline Characteristics

    CONNECT - FX: Demographics and Baseline Characteristics 16 Similar in the Full Data Set and FMet Group Full Data Set Group FMet Group Placebo Zygel Total Placebo Zygel Total n 102 110 212 77 92 169 Age (years) 9.8 9.6 9.7 9.6 9.2 9.4 Sex – Males (%) 78 (76%) 81 (74%) 159 (75%) 54 (70%) 65 (71%) 119

  17. Slide 17: Pre-Planned Ad Hoc Results: FMet Group

    Pre - Planned Ad Hoc Results: FMet Group 17 Zygel Achieved Statistical Significance on Social Avoidance: Changes From Baseline to Week 12 (ABC - C FXS ) Placebo N=76 Zygel N=91 Endpoints Baseline Mean (SE) Week 12 Mean (SE) Week 12 Median Percent Change Baseline Mean (SE) Week 12 Mean (SE) Week 12 M

  18. Slide 18: ABC-C FXS Social Avoidance Changes in FMet Group

    CONNECT - FX: ABC - C FXS Social Avoidance Changes From Baseline to Week 12 in FMet Group 18 In placebo group, the most common change (mode) in Social Avoidance was zero 0 2 4 6 8 10 12 14 16 18 20 22 24 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 Placebo (n=75) Number of patients Change from bas

  19. Slide 19: Zygel group demonstrated greater improvement versus placebo

    19 Zygel group demonstrated greater improvement versus placebo 0 2 4 6 8 10 12 14 16 18 20 22 24 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 Zygel (n=88) Placebo mode = 0 Zygel mode = −4 Nearly twice (1.9x) as many Zygel children experienced changes of 4 or more points relative to placebo (n=36 v

  20. Slide 20: Caregiver Global Impression - Change: FMet Group

    CONNECT - FX: Caregiver Global Impression - Change: FMet Group 0 10 20 30 40 50 60 70 Placebo Zygel Change from Baseline to Week 12: Broad Shifts Towards Global Improvement Placebo Zygel Placebo Zygel Placebo Zygel Overall Behavior Social Interactions Irritable and Disruptive Behaviors Social Avoida

  21. Slide 21: Psychometric Analyses Determined Clinically Meaningful Changes for ABC-C FXS

    Psychometric Analyses Determined Clinically Meaningful Changes for ABC - C FXS 21 • Clinically meaningful treatment responses over 12 weeks of treatment determined to be an improvement of: • Three (3) points or greater for the Social Avoidance subscale • Nine (9) points or greater for the Irritabili

  22. Slide 22: FMet Patients With Clinically Meaningful Change in ABC-C FXS Subscales

    22 FMet Patients With Clinically Meaningful Change in ABC - C FXS Subscales 40.6 58.2 0 10 20 30 40 50 60 70 Placebo Zygel Data reported at the 2020 Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting 23.8 40.3 Placebo Zygel Socially Unrespons

  23. Slide 23: Zygel Advantages Observed in Social Avoidance Are Supported

    Zygel Advantages Observed in Social Avoidance Are Supported by Caregiver and Clinical Global Impression Improvements in FMet Group * Statistically significant ** Not specific to Social Avoidance 23 Primary Endpoint: ABC - C FXS Social Avoidance Subscale • Statistically significantly improvement vs.

  24. Slide 24: CONNECT-FX: Safety

    CONNECT - FX: Safety 24 • Zygel was very well tolerated • Safety profile consistent with previously released data from all other Zygel trials • No safety signal identified • No serious or severe adverse events reported during the study • All treatment - emergent adverse events (TEAEs; any event, whe

  25. Slide 25: Next Steps in Fragile X Program

    Next Steps in Fragile X Program 25 • In 4Q2020, Zynerba expects to announce the outcome of its meeting with the FDA and the regulatory path forward in FMet patients • Additional data to be published and presented at upcoming medical meetings

  26. Slide 26: Autism Spectrum Disorder (ASD) in children and adolescents

    26 Autism Spectrum Disorder (ASD) in children and adolescents

  27. Slide 27: ASD in Pediatrics Overview

    ASD in Pediatrics Overview 27 • Near - rare disorder affecting ~1MM pediatric and adolescent patients • Symptoms include • Irritability • Anxiety • Restricted, repetitive patterns of behavior • Impairments in social communication • Deficits in verbal and non - verbal communication • Deficits in deve

  28. Slide 28: Rationale for Developing Zygel in ASD

    Rationale for Developing Zygel in ASD 28 • Newer studies suggest ASD is linked to disruption in the EC system • Altered anandamide signaling may contribute to ASD - related social and communication impairments • EC system modulates many cellular functions and molecular pathways altered in ASD: imbal

  29. Slide 29: BRIGHT Phase 2 Trial in ASD

    BRIGHT Phase 2 Trial in ASD 29 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder 37 patients enrolled Three through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: COMP

  30. Slide 30: Baseline Patient Population: BRIGHT

    Baseline Patient Population: BRIGHT Patients enrolled (n) 37 Included in safety analysis 37 Included in efficacy analyses 36* Discontinuations 9 Patients completing 14 - week trial 28 BRIGHT Trial Patient Populations 30 * One patient was lost to follow up and did not have post - dosing efficacy asse

  31. Slide 31: Baseline Patient Demographics

    Baseline Patient Demographics Patients enrolled, n 37 Age, years Mean (range) 9.2 (3 - 16) Sex, n (%) Male Female 34 (91.9%) 3 (8.1%) Race, % White Asian Native Hawaiian or othe r Pacific Island Other 70.3% 8.1% 2.7% 18.9% Time to diagnosis, years 5.4 Underlying medication, % Subjects entering with

  32. Slide 32: Strong Safety and Tolerability Profile in BRIGHT Trial in ASD

    • Well tolerated; consistent with previously released data • Fewer than half of patients experienced an adverse event (AE); most were mild and transient • Only 14% of patients experienced a treatment - related AE • All application site - related • No severe or serious AEs reported during the study.

  33. Slide 33: Percent Improvement in ABC-C Subscale Scores at Week 14

    33 0 5 10 15 20 25 30 35 40 45 Irritability Inappropriate Speech Stereotypy Social withdrawal Hyperactivity Baseline: 30.3 Baseline: 12.3 Baseline: 7.4 Baseline: 37.0 Baseline: 25.1 39.1% 42.5% 35.6% 36.4% 42.6% Mean % Improvement from Baseline 39.1% * Statistically significant p<0.0001* Statistical

  34. Slide 34: ABC-C Responses Supported by Other Efficacy Assessments

    Results of other efficacy assessments support the results demonstrated in the ABC - C, including: • Parent Rated Anxiety Scale - Autism Spectrum Disorder (PRAS - ASD): • Mean improvement of 46% at week 14 from baseline (p<0.0001) • Clinical Global Impression - Improvement (CGI - I) • 57% of patients

  35. Slide 35: Statistically Significant Improvements in Autism Impact Measure Scores

    35 Statistically Significant Improvements in Autism Impact Measure Scores 44.0 39.3 31.2 54.0 33.9 29.9 32.7 25.4 36.4 30.4 0 10 20 30 40 50 60 Atypical Behavior Communication Peer Interaction Repetitive Behavior Social Reciprocity AIM Scale Score 34.1% ( P <0.001) 19.7% ( P <0.001) 19.8% ( P <0.001

  36. Slide 36: Statistically Significant Improvement in Autism Parenting Stress Index

    36 Statistically Significant Improvement: in Autism Parenting Stress Index Additional improvements in the Qualitative Caregiver Behavioral Problems Survey Phase 2 BRIGHT Trial Autism Parenting Stress Index 38.9% ( P <0.0001) 36.0 22.9 0 5 10 15 20 25 30 35 40 APSI Baseline Week 14 Mean APSI Score Ab

  37. Slide 37: Next Steps in ASD Program

    Next Steps in ASD Program 37 • Zynerba Intends to discuss the results of the Phase 2 BRIGHT trial and the path forward with the FDA in 1H2021 • Present additional data at future medical meetings

  38. Slide 38: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome (22q) 38

  39. Slide 39: 22q Overview

    22q Overview 39 • Most common contiguous gene deletion syndrome • Rare disorder: ~81K patients in US • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities

  40. Slide 40: 22q Patient Management

    22q Patient Management 40 • Two primary stages of 22q patient management: • During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery • Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety an

  41. Slide 41: Rationale for Developing Zygel in 22q

    Rationale for Developing Zygel in 22q 41 • Cannabidiol may treat neuropsychiatric symptoms in 22q due to activity as: • Modulator of endocannabinoid system • Agonist at serotonin 1A receptors • Antagonist at GPR55 receptors • Early control of anxiety may delay the development of psychosis • Phase 2

  42. Slide 42: INSPIRE Phase 2 Trial in 22q

    INSPIRE Phase 2 Trial in 22q 42 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily Efficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community (ABC - C) • Anxiety, Depression and Mood Scale (

  43. Slide 43: DEE Developmental and Epileptic Encephalopathies

    DEE Developmental and Epileptic Encephalopathies 43

  44. Slide 44: DEE Patients are Medically Fragile

    DEE Patients are Medically Fragile 44 • Group of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral p

  45. Slide 45: BELIEVE Phase 2 Trial in DEE

    BELIEVE Phase 2 Trial in DEE 45 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titr

  46. Slide 46: BELIEVE: Clinically Meaningful Seizure Reductions Sustained Through Six Months

    46 BELIEVE: Clinically Meaningful Seizure Reductions from Baseline and Sustained through Six Months in DEE 0 10 20 30 40 50 60 70 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Median Percent Reduction from Baseline, FIAS and CS N=33 N=33 N=33 N=32 N=32 N=29 16% 44% 44% 47% 58% 51% Median Percent R

  47. Slide 47: BELIEVE: Percentage of Patients with ≥35% and ≥50% Reduction

    BELIEVE: Percentage of Patients with ≥35% and ≥50% Reduction in FIAS and TCS 47 Data reported at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session ≥35% and ≥50% Reduction in FIAS and TCS by Time Point, mITT Population With FIAS and/or TCS at Baseline (n = 33)

  48. Slide 48: BELIEVE Safety

    48 • All events in six month period, whether unrelated or related to study drug, reported as adverse AEs (e.g.: influenza, runny nose, scrapes, etc.) • As a result and as anticipated, most patients experienced an AE • Most were mild and transient • Only one patient discontinued due to an AE (applica

  49. Slide 49: BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements

    49 BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements • Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale • Statistically significant reductions from baseline in subscale scores for seizure severity, behavior, and mood observed at month 6 (p<0.01) • Qualitative

  50. Slide 50: BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements

    50 BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements • Good Day/Bad Day comparing baseline to month six: • “Good day” and “fantastic day” reports increased from 52% to 70% • “Terrible day” and “bad day” reports decreased from 12% to 4% Data reported at the 2020 American Acade

  51. Slide 51: Compelling Results Suggest a Potential Pathway to Pivotal Trials

    51 • Efficacy results: • Clinically meaningful reductions in seizures beginning in month two and sustained through six months • Suggest improvements on important behavioral symptoms • Safety results: • Zygel was well tolerated • Consistent with previously reported Zygel studies • The FDA supports a

  52. Slide 52: Financial Strength

    Financial Strength 52 • Clean balance sheet • No debt, 29.4 M shares outstanding (as of November 5, 2020) • Cash and cash equivalent position of $64.3M as of September 30, 2020 • Cash runway expected to be sufficient to fund operations and capital requirements until late in the fourth quarter of 202

  53. Slide 53: Expected Clinical Milestones in 2020

    Expected Clinical Milestones in 2020 53 FXS DEE Report pivotal CONNECT - FX topline results ASD * 22q 1Q 2020 2Q 2020 Report Ph. 2 BRIGHT topline results 3Q 2020 4Q 2020 Results of FDA discussions on clinical path Discuss results in FMet pts with FDA & disclose outcome Enrollment delayed due to COVI

  54. Slide 54: Corporate Overview November 2020

    Corporate Overview November 2020

Zynerba Pharmaceuticals — Investor Presentation (November 2020) on 6ix